Ann: ACTION3 IND Approved in China, page-145

why not try reading stuff that's out there, like this
https://www.fdanews.com/articles/208909-fda-declines-traveres-second-attempt-at-accelerated-approval-for-sparsentan
and this
https://ir.travere.com/news-releases/news-release-details/travere-completes-successful-pre-nda-meeting-filspari-igan

#trevere completed the largest ever phase3 trialy in fsg called "duplex". better phase2 data than the dimx asset
#excellent statistically significant interim result on proteinuria in phase3. FDA still said no to accelerated. Twice.
#the reasoning is laid bare. only a complete fool with head buried in sand thinks none of this is relevant
#what's so special about the dimx asset that make you think FDA will give them free pass to accelerated? I just don't see it. other ccr2 inhibitor from CSL failed in its fsg trial, no better than placebo
https://newsroom.csl.com/2020-05-18-VFMCRP-Press-Release-Phase-ii-Lumina-1-Trial-of-Ccx140
#question if this method of action is that effective in fsg disease but we'll know for certain once dimx phase3 finishes in few years